MLLT10 and acute lymphoblastic leukemia: Here, we report the case of a primary refractory pediatric patient suffering from a PICALM::MLLT10 + BCP-ALL, who could be salvaged by venetoclax identified by prospective ex vivo drug response profiling (DRP) as the only active drug.